Are Research Peptides Legal in Australia? The Framework, the Scheduling and the 2026 Enforcement Record

Australian law has no category called "research peptides". It has therapeutic goods, defined by how a product is presented and what it is likely to be taken for, with a scheduling instrument across the top. During 2026 the Therapeutic Goods Administration made peptides a named compliance priority and took a series of public actions, so the risk attached to getting this wrong is documented rather than theoretical. This page sets out the framework, which peptides are scheduled, what a "research use only" label does and does not change, and the 2026 enforcement record. It is general information, not legal advice.

The framework turns on presentation, not chemistry

Peptide products are regulated as therapeutic goods under the Therapeutic Goods Act 1989, and several peptide medicines — insulins, for example — are approved and included in the Australian Register of Therapeutic Goods (ARTG) ^[1]. "Unapproved" simply means not included in the ARTG, and therefore not assessed by the TGA for safety, quality or efficacy ^[1].

What makes something a therapeutic good is the statutory definition in section 3 of the Act: goods represented in any way to be, or that are likely to be taken to be, for therapeutic use, whether because of the way they are presented or for any other reason, plus goods in a class whose sole or principal use ordinarily is therapeutic ^[2]. Therapeutic use is defined broadly, including influencing, inhibiting or modifying a physiological process in a person ^[2]. The TGA adds that a product containing an ingredient in Schedules 2, 3, 4 or 8 of the Poisons Standard is likely to be a therapeutic good, those ingredients belonging to classes whose ordinary use is therapeutic ^[2].

Two consequences follow. The molecule's identity is not the only question; so is everything said and shown around it. And an intended laboratory use does not place a scheduled substance outside the supply controls — a point the Poisons Standard itself makes.

The TGA names BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as examples of unapproved peptide products, and lists adverse events reported to it for such products: severe allergic reactions requiring adrenaline and hospitalisation, systemic inflammatory response syndrome, generalised hypersensitivity, musculoskeletal injuries including Achilles tendinitis, and poor product quality such as unsealed packaging from an online supplier ^[1].

What the Poisons Standard does and does not do

The Poisons Standard — formally the Therapeutic Goods (Poisons Standard — October 2026) Instrument 2026, made under paragraph 52D(2)(b) of the Act — classifies substances into schedules as recommendations to the states and territories, and its scheduling is implemented through state and territory legislation ^[3]. Schedule 4 covers prescription-only medicines: substances whose use or supply should be by or on the order of a person permitted to prescribe, available from a pharmacist on prescription ^[3].

Three features of that table matter more than the list itself.

Appendix D is the sharp end. Clause 5 of Appendix D specifies poisons that "must not be possessed by a person without authority", including BPC-157, TB-500, thymosin β4, CJC-1295, AOD-9604, ipamorelin, hexarelin, GHRP-6, pralmorelin, insulin-like growth factors, somatropin and the GHRH, GHRP and secretagogue class entries ^[3]. Section 64 gives that effect: such a poison must not be possessed without authority under the law of the jurisdiction where possession occurs ^[3]. Possession, not just supply — and the operative authority is state or territory law.

The laboratory exemption is narrower than it looks. The instrument's introduction states that poisons packed and sold solely for industrial, manufacturing, laboratory or dispensary use are exempt from all labelling requirements in the instrument, because work health and safety law covers those labels, and then says expressly that "this exemption does not extend to controls on supply of these poisons" ^[3]. A laboratory presentation can change labelling obligations; it does not switch off section 60, which restricts who may supply a Schedule 4 poison ^[3].

Class entries catch unnamed compounds. Because GHRHs, GHRPs and growth hormone secretagogues are scheduled as classes, a compound can fall inside Schedule 4 and Appendix D without appearing under its own name ^[3]. Conversely, absence from the instrument — retatrutide, for instance — does not mean absence of regulation: the therapeutic goods framework applies independently ^[1].

Scheduling also restricts advertising directly. Section 57 provides that a reference to a Schedule 4 poison must not appear in any advertisement except in genuine professional or trade journals, or publications intended to circulate only within the medical, nursing, veterinary, dental or pharmaceutical professions or the wholesale drug industry ^[3].

"Research use only": what the label does and does not change

The TGA has addressed this disclaimer head-on. Its April 2026 advisory states that disclaimers that a product is for "research use only" do not change a product's regulatory status, do not permit importation, and do not remove advertising or supply obligations, and adds that state and territory laws may impose further controls on sale, supply and possession ^[1]. Products "labelled to avoid regulatory scrutiny" are unlikely to be released at the border, including those with omitted ingredients, obscured or over-labelled information, or unlabelled vials ^[1]. A legal commentary on the sector makes the same observation from the other side: peptides are commonly sold in Australia with "for research use only" or "not for human use" indications while remaining unapproved ^[4].

What the label does do is define the supplier's own representations — and that pulls in consumer law. Under the Australian Consumer Law it is unlawful to engage in conduct that is misleading or deceptive or likely to mislead or deceive (sections 18–19), and the test is the overall impression created, judged against an ordinary or reasonable member of the relevant class of consumers; intention is irrelevant, silence can mislead, and in most cases a business cannot rely on small print or disclaimers to cure an otherwise misleading message ^[5]. Separately, sections 29–34 prohibit false or misleading representations about matters including the standard, quality, value or grade of goods, their composition, and their performance characteristics, with remedies ranging from injunctions and corrective advertising to pecuniary penalties ^[5].

Read together, the two bodies of law close the loop that some marketing tries to open: a research-use disclaimer sitting under content implying human use is both a therapeutic goods problem and a consumer law problem. The test for any page, label or message is what its overall impression conveys.

Advertising: the rule that generates most enforcement

Advertising of prescription-only medicines to the public is prohibited unless authorised or required by an Australian government authority, and it is also unlawful to advertise certain goods not in the ARTG to the public, however and wherever they are promoted ^[1]. The TGA regulates advertisements for both approved and unapproved peptide products, and states that influencers, affiliates, online sellers and anyone else promoting unapproved peptide products may be held accountable for unlawful advertising ^[6].

On top of that sit the Advertising Code's representation rules. Restricted representations refer to serious forms of disease, condition, ailment or defect — those requiring a health professional to diagnose, follow up or treat — and may not be used without TGA approval or permission ^[7]. Prohibited representations concern the treatment, cure, prevention, diagnosis or monitoring of, or susceptibility to, neoplastic diseases, sexually transmitted diseases, HIV or AIDS, hepatitis C and mental illness; these cannot be applied for at all, and the TGA may permit them only where necessary for public health or appropriate use ^[7]. Significant fines and penalties apply to using either without prior approval ^[7].

The 2026 enforcement record

Peptides moved from general warnings to a named priority during 2026. The TGA expanded its compliance focus areas to include unapproved peptide products in June 2026, citing increased detection of unlawful importation, supply and advertising, and referred to a joint operation with Australian Border Force and Victoria Police that seized peptides, performance and image enhancing drugs and illicit steroids with an estimated street value above $2 million ^[8].

The BioV8 matter shows how the advertising rules bite: the allegation is that peptides were promoted for serious diseases including cancer, HIV/AIDS and mental illnesses — restricted and prohibited representations — and that the two former directors aided, abetted, counselled or procured the conduct; declarations and pecuniary penalties are sought, and proceeding against the company in liquidation requires the Court's leave ^[12]. The TGA's stated position is that it will act against all entities operating unlawfully in the peptide industry, including health practitioners, compounding pharmacies, social media influencers and telehealth clinics ^[12].

None of this is new in kind. A 2026 legal review notes that the Federal Court ordered Peptide Clinics to pay $10 million in penalties on 23 July 2019 over unlawful advertising and supply of prescription-only therapeutics, and that in March 2024 the TGA executed a search warrant on a South Yarra pharmacy, seizing semaglutide, peptides and human growth hormones allegedly unlawfully manufactured ^[4]. It also sets out the lawful access route — prescription by a medical practitioner, or in some cases a nurse practitioner within scope, with compounding by a pharmacist — while noting that medical regulators have tended to be hostile to practitioners prescribing peptides ^[4]. Compounding exemptions are narrow: a compounded good is generally exempt from ARTG inclusion only where it is compounded for a particular person for application to that person, or in a hospital in anticipation of need, and Schedule 8 of the Therapeutic Goods Regulations 1990 governs when a manufacturing licence is nonetheless required ^[1].

Why the quality argument and the legal argument are the same argument

The regulator's safety case rests on provenance: products assessed by nobody, labelled unreliably, of unknown sterility and content ^{[1, 9]}. A 2024 study of semaglutide sold online without prescription test-purchased products from illegal online pharmacies, found that none of three ordered prefilled pens arrived, and measured in the delivered vials semaglutide content 28.6–38.7% above the labelled amount, purity of 7.7–14.4% against a 99% label claim, and detectable endotoxin in every sample ^[13]. Forensic laboratories have had to characterise melanotan II and bremelanotide from unlabelled black-market samples without reference standards, using high-resolution mass spectrometry to establish what the material even was ^[14].

For a laboratory buyer the lesson is unglamorous: batch-level identity and purity documentation is both the scientific minimum and the only way to know what is in your possession. See understanding certificates of analysis for what those documents can and cannot show, what HPLC testing measures for the purity figure, and how to choose a peptide supplier for the questions worth asking. Every batch we supply is tested by HPLC against a ≥99% purity specification with identity confirmed by mass spectrometry, and batch documentation is available on request; our products are supplied as lyophilised reagents for in-vitro laboratory research only and are not for human or veterinary use, as our terms and editorial policy set out.

Where that leaves a researcher

• Check the schedule entry for your compound, class entries included, before assuming anything about possession or supply in your jurisdiction; the instrument is amended several times a year ^[3].
• Do not treat a research-use label as a permission. The TGA has said in terms that it changes neither regulatory status, nor importation rights, nor advertising and supply obligations ^[1].
• Expect import scrutiny. Unlabelled, code-labelled or incompletely described vials are the specific trigger the TGA says it refers to Border Force for seizure and destruction, with no compensation ^{[9, 15]}.
• Keep records that identify material unambiguously — batch numbers, identity and purity data, storage history; the deficiencies regulators and analysts report are overwhelmingly documentation and provenance failures ^{[1, 13]}.
• Get advice about your own activity. Importation, supply, manufacture (defined broadly enough to include labelling a blank vial or storing stock before final form) and advertising each carry separate obligations and penalties ^{[6, 11]}.

For the compounds rather than the law, the immunomodulatory peptides guide and the neuropeptides guide cover evidence quality, and the research index lists the rest; batch questions go through our contact page or the FAQ.